The AI Prognostic Assessment and Pathological Basis Research of Early HCC After Minimally Invasive Treatment
NCT ID: NCT04299919
Last Updated: 2020-03-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1200 participants
OBSERVATIONAL
2007-04-01
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma
NCT03198975
Precision Recurrence Risk Assessment in Early-stage Hepatocellular Carcinoma
NCT07030842
Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)
NCT07059936
The Evaluation of Surgical Decisions and Prognosis of the Radiomics and Watson Artificial Intelligence in Patients With Hepatocellular Carcinoma
NCT03917017
Artificially Intelligent Model for Accurate Detection of HCC
NCT06637059
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Recurrence
All hepatocellular carcinoma (HCC) patients have been regularly monitored for recurrence via contrast CT or contrast-enhanced MRI after minimally invasive treatment or hepatectomy. The recurrence status included new intrahepatic lesions and/or extrahepatic metastasis.
Minimally invasive treatment
All hepatocellular carcinoma (HCC) patients received minimally invasive treatment, including transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA) or combined.
Hepatectomy
All hepatocellular carcinoma (HCC) patients received hepatectomy.
Non-recurrence
All hepatocellular carcinoma (HCC) patients have been regularly monitored for recurrence via contrast CT or contrast-enhanced MRI after minimally invasive treatment or hepatectomy. The recurrence status included new intrahepatic lesions and/or extrahepatic metastasis.
Minimally invasive treatment
All hepatocellular carcinoma (HCC) patients received minimally invasive treatment, including transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA) or combined.
Hepatectomy
All hepatocellular carcinoma (HCC) patients received hepatectomy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Minimally invasive treatment
All hepatocellular carcinoma (HCC) patients received minimally invasive treatment, including transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA) or combined.
Hepatectomy
All hepatocellular carcinoma (HCC) patients received hepatectomy.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients received MRI examination within 1 month before treatment;
* Complete post-treatment prognosis information.
Exclusion Criteria
* Incomplete clinical and pathological data;
* Heavy image artifacts.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First Affiliated Hospital of Dalian Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ying Zhao, MD
Role: STUDY_CHAIR
The First Affiliated Hospital of Dalian Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bloomston M, Binitie O, Fraiji E, Murr M, Zervos E, Goldin S, Kudryk B, Zwiebel B, Black T, Fargher S, Rosemurgy AS. Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. Am Surg. 2002 Sep;68(9):827-31.
Ye JZ, Chen JZ, Li ZH, Bai T, Chen J, Zhu SL, Li LQ, Wu FX. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion. World J Gastroenterol. 2017 Nov 7;23(41):7415-7424. doi: 10.3748/wjg.v23.i41.7415.
Li S, Zhang L, Huang ZM, Wu PH. Transcatheter arterial chemoembolization combined with CT-guided percutaneous thermal ablation versus hepatectomy in the treatment of hepatocellular carcinoma. Chin J Cancer. 2015 Jun 10;34(6):254-63. doi: 10.1186/s40880-015-0023-9.
Pang Q, Zhang JY, Xu XS, Song SD, Chen W, Zhou YY, Miao RC, Qu K, Liu SS, Dong YF, Liu C. The prognostic values of 12 cirrhosis-relative noninvasive models in patients with hepatocellular carcinoma. Scand J Clin Lab Invest. 2015 Jan;75(1):73-84. doi: 10.3109/00365513.2014.981759. Epub 2014 Dec 3.
Kim NH, Lee T, Cho YK, Kim BI, Kim HJ. Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization. J Gastroenterol Hepatol. 2018 Jul;33(7):1397-1406. doi: 10.1111/jgh.14083. Epub 2018 Mar 12.
Yasaka K, Akai H, Abe O, Kiryu S. Deep Learning with Convolutional Neural Network for Differentiation of Liver Masses at Dynamic Contrast-enhanced CT: A Preliminary Study. Radiology. 2018 Mar;286(3):887-896. doi: 10.1148/radiol.2017170706. Epub 2017 Oct 23.
Ibragimov B, Toesca D, Chang D, Koong A, Xing L. Combining deep learning with anatomical analysis for segmentation of the portal vein for liver SBRT planning. Phys Med Biol. 2017 Nov 10;62(23):8943-8958. doi: 10.1088/1361-6560/aa9262.
Song W, Yu X, Guo D, Liu H, Tang Z, Liu X, Zhou J, Zhang H, Liu Y, Liu X. MRI-Based Radiomics: Associations With the Recurrence-Free Survival of Patients With Hepatocellular Carcinoma Treated With Conventional Transcatheter Arterial Chemoembolization. J Magn Reson Imaging. 2020 Aug;52(2):461-473. doi: 10.1002/jmri.26977. Epub 2019 Nov 1.
Hui TCH, Chuah TK, Low HM, Tan CH. Predicting early recurrence of hepatocellular carcinoma with texture analysis of preoperative MRI: a radiomics study. Clin Radiol. 2018 Dec;73(12):1056.e11-1056.e16. doi: 10.1016/j.crad.2018.07.109. Epub 2018 Sep 10.
Wu M, Tan H, Gao F, Hai J, Ning P, Chen J, Zhu S, Wang M, Dou S, Shi D. Predicting the grade of hepatocellular carcinoma based on non-contrast-enhanced MRI radiomics signature. Eur Radiol. 2019 Jun;29(6):2802-2811. doi: 10.1007/s00330-018-5787-2. Epub 2018 Nov 7.
Li Z, Mao Y, Huang W, Li H, Zhu J, Li W, Li B. Texture-based classification of different single liver lesion based on SPAIR T2W MRI images. BMC Med Imaging. 2017 Jul 13;17(1):42. doi: 10.1186/s12880-017-0212-x.
Kim J, Choi SJ, Lee SH, Lee HY, Park H. Predicting Survival Using Pretreatment CT for Patients With Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: Comparison of Models Using Radiomics. AJR Am J Roentgenol. 2018 Nov;211(5):1026-1034. doi: 10.2214/AJR.18.19507. Epub 2018 Sep 21.
Zhou Y, He L, Huang Y, Chen S, Wu P, Ye W, Liu Z, Liang C. CT-based radiomics signature: a potential biomarker for preoperative prediction of early recurrence in hepatocellular carcinoma. Abdom Radiol (NY). 2017 Jun;42(6):1695-1704. doi: 10.1007/s00261-017-1072-0.
Huang YL, Chen JH, Shen WC. Diagnosis of hepatic tumors with texture analysis in nonenhanced computed tomography images. Acad Radiol. 2006 Jun;13(6):713-20. doi: 10.1016/j.acra.2005.07.014.
Tang H, Bai HX, Su C, Lee AM, Yang L. The effect of cirrhosis on radiogenomic biomarker's ability to predict microvascular invasion and outcome in hepatocellular carcinoma. Hepatology. 2016 Aug;64(2):691-2. doi: 10.1002/hep.28620. Epub 2016 May 31. No abstract available.
Wu LF, Rao SX, Xu PJ, Yang L, Chen CZ, Liu H, Huang JF, Fu CX, Halim A, Zeng MS. Pre-TACE kurtosis of ADCtotal derived from histogram analysis for diffusion-weighted imaging is the best independent predictor of prognosis in hepatocellular carcinoma. Eur Radiol. 2019 Jan;29(1):213-223. doi: 10.1007/s00330-018-5482-3. Epub 2018 Jun 19.
Shao GL, Zheng JP, Guo LW, Chen YT, Zeng H, Yao Z. Evaluation of efficacy of transcatheter arterial chemoembolization combined with computed tomography-guided radiofrequency ablation for hepatocellular carcinoma using magnetic resonance diffusion weighted imaging and computed tomography perfusion imaging: A prospective study. Medicine (Baltimore). 2017 Jan;96(3):e5518. doi: 10.1097/MD.0000000000005518.
Wang J, Shen JL. Spectral CT in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma: A retrospective study. Medicine (Baltimore). 2017 Dec;96(52):e9236. doi: 10.1097/MD.0000000000009236.
Hasdemir DB, Davila LA, Schweitzer N, Meyer BC, Koch A, Vogel A, Wacker F, Rodt T. Evaluation of CT vascularization patterns for survival prognosis in patients with hepatocellular carcinoma treated by conventional TACE. Diagn Interv Radiol. 2017 May-Jun;23(3):217-222. doi: 10.5152/dir.2016.16006.
Lam A, Fernando D, Sirlin CC, Nayyar M, Goodwin SC, Imagawa DK, Lall C. Value of the portal venous phase in evaluation of treated hepatocellular carcinoma following transcatheter arterial chemoembolisation. Clin Radiol. 2017 Nov;72(11):994.e9-994.e16. doi: 10.1016/j.crad.2017.07.003. Epub 2017 Aug 2.
Choi JW, Chung JW, Lee DH, Kim HC, Hur S, Lee M, Jae HJ. Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma. Eur Radiol. 2018 May;28(5):2184-2193. doi: 10.1007/s00330-017-5145-9. Epub 2017 Dec 7.
Related Links
Access external resources that provide additional context or updates about the study.
Transcatheter arterial chemoembolization.
Efficacy of postoperative in hepatocellular carcinoma patients with microvascular invasion.
Transcatheter arterial chemoembolization.
The prognostic values.
Portal hypertension.
Deep Learning.
The segmentation of the portal vein.
MRI-Based Radiomics.
A radiomics study.
Predicting the grade of hepatocellular carcinoma.
Texture-based classification of different single liver lesion.
Comparison of Models Using Radiomics.
CT-based radiomics signature.
Diagnosis of hepatic tumors with texture analysis.
The predicting microvascular invasion and outcome in hepatocellular carcinoma.
The best independent predictor of prognosis in hepatocellular carcinoma.
Evaluation of the efficacy of hepatocellular carcinoma.
The therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma.
The survival prognosis in patients with hepatocellular carcinoma treated by conventional TACE.
Transcatheter arterial chemoembolisation.
Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PJ-KS-KY-2019-167
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.